Free from Publisher

Long-term follow-up and outcomes of retreatment in an expanded 50-patient single-center phase II prospective trial of 177Lu-PSMA-617 theranostics in metastatic …

J Violet, S Sandhu, A Iravani… - Journal of Nuclear …, 2020 - Soc Nuclear Med
177Lu-PSMA-617 is a radioligand with high affinity for prostate-specific membrane antigen
(PSMA), enabling targeted β-irradiation of prostate cancer. We have previously reported …
被引用次数：247 相关文章

Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of 177Lu-PSMA-617 Theranostics in …

J Violet, S Sandhu, A Iravani, J Ferdinandus… - Journal of Nuclear …, 2019 - europepmc.org
Abstract 177 Lu-PSMA-617 is a radioligand with high affinity for prostate-specific membrane
antigen (PSMA), enabling targeted β-irradiation of prostate cancer. We have previously …

Long-term follow-up and outcomes of retreatment in an expanded 50-patient single-center Phase II prospective trial of 177Lu-PSMA-617 theranostics in metastatic …

J Violet, S Sandhu, A Iravani… - Journal of Nuclear …, 2020 - profiles.wustl.edu
Abstract 177 Lu-PSMA-617 is a radioligand with high affinity for prostate-specific membrane
antigen (PSMA), enabling targeted β-irradiation of prostate cancer. We have previously …

[引用][C] Long-term follow-up and outcomes of retreatment in an expanded 50-patient single-center phase II prospective trial of 177Lu-PSMA-617 theranostics in …

J Violet, S Sandhu, A Iravani… - Journal of Nuclear …, 2020 - espace.library.uq.edu.au
Lu-177-PSMA-617 is a radioligand with high affinity for prostate-specific membrane antigen
(PSMA), enabling targeted beta-irradiation of prostate cancer. We have previously reported …
[HTML] nih.gov

[HTML][HTML] Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of 177Lu-PSMA-617 Theranostics in …

J Violet, S Sandhu, A Iravani… - Journal of Nuclear …, 2020 - ncbi.nlm.nih.gov
Abstract 177 Lu-PSMA-617 is a radioligand with high affinity for prostate-specific membrane
antigen (PSMA), enabling targeted β-irradiation of prostate cancer. We have previously …
[PDF] snmjournals.org

[PDF][PDF] Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of 177Lu-PSMA-617 Theranostics in …

J Violet, S Sandhu, A Iravani, J Ferdinandus… - J Nucl …, 2020 - Soc Nuclear Med
177Lu-PSMA-617 is a radioligand with high affinity for prostate-specific membrane antigen
(PSMA), enabling targeted β-irradiation of prostate cancer. We have previously reported …

[引用][C] Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of 177Lu-PSMA-617 Theranostics in …

J Violet, S Sandhu, A Iravani, J Ferdinandus… - Journal of Nuclear …, 2019 - cir.nii.ac.jp
Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center
Phase II Prospective Trial of <sup>177</sup>Lu-PSMA-617 Theranostics in Metastatic …

Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of 177Lu-PSMA-617 Theranostics in …

J Violet, S Sandhu, A Iravani… - Journal of nuclear …, 2020 - pubmed.ncbi.nlm.nih.gov
177 Lu-PSMA-617 is a radioligand with high affinity for prostate-specific membrane antigen
(PSMA), enabling targeted β-irradiation of prostate cancer. We have previously reported …